A first-in-human trial investigating TG-6002 in glioblastoma patients

Trial Profile

A first-in-human trial investigating TG-6002 in glioblastoma patients

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs TG 6002 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Mar 2017 According to a Transgene media release, this trial is expected to start in 2Q 2017. INCA (French national cancer institute) will support this trial.
    • 05 Oct 2016 According to a Transgene media release, this trial will be conducted at Assistance Publique-Hopitaux de Paris (AP-HP) with Pr. Delattre as principal investigator.
    • 05 Sep 2016 According to a Transgene media release, this trial is expected to start in first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top